Chimerix (CMRX) Set to Announce Quarterly Earnings on Wednesday

Chimerix (NASDAQ:CMRX) will be announcing its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. Chimerix had a negative return on equity of 37.93% and a negative net margin of 25,337.96%. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Stock Up 1.6 %

CMRX traded up $0.02 during trading on Tuesday, hitting $0.95. 149,535 shares of the stock were exchanged, compared to its average volume of 384,965. The firm has a market capitalization of $84.74 million, a P/E ratio of -1.02 and a beta of 1.15. Chimerix has a 1-year low of $0.88 and a 1-year high of $1.57. The stock has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.00.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CMRX. Wedbush reissued an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a report on Monday, February 12th. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Monday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chimerix in a report on Friday, March 1st.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.